The analyst highlights Amgen's veteran status in drug manufacturing, focusing on diverse treatments for chronic conditions, with revenue reaching nearly $36.7 billion in FY 2025 and a net income of approximately $7.7 billion. In contrast, Moderna, a biotechnology pioneer, reported revenue close to $1.9 billion in FY 2025, a 39.2% decline, and a net loss of nearly $2.8 billion, reflecting high R&D costs relative to sales. The recommendation for Amgen is based on its profitable, dividend-paying status and strong execution, while Moderna's investment case heavily relies on future clinical trial outcomes.